High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects

Published:August 03, 2016DOI:


      • It is already known that SUA is a predictor of incident hypertension
      • Our data add information on the role of SUA as a factor associated with poor BP control despite antihypertensive therapy
      • This could be related to the negative effect of SUA on arterial stiffness



      Serum uric acid (SUA) has been associated to incident hypertension and increased risk of cardiovascular diseases.

      Materials and methods

      Among the 2191 subjects enrolled during the last population survey of the Brisighella Heart Study, we identified 146 new cases of arterial hypertension and 394 treated but uncontrolled hypertensive patients with different levels of SUA. Their hemodynamic characteristics have been compared with those of age- and sex-matched normotensive (N. 324) and controlled hypertensive (N. 470) subjects. Then, by logistic regression analysis, we evaluated which factors were associated with a worse BP control under pharmacological treatment.


      SUA levels were significantly higher in untreated hypertensive and uncontrolled hypertensive patients when compared to normotensives and controlled hypertensive patients. Pulse wave velocity (PWV) was significantly higher (p < 0.001) in undiagnosed and uncontrolled hypertensive patients, while controlled hypertensive patients had PWV values comparable to normotensive controls. A similar trend has been observed for the augmentation index (AI). A worse BP control was associated with SUA levels (OR 1277, 95% CI 1134–1600 per mg/dL), AI (OR 1066, 95%CI 1041–1092 per unit), and PWV (OR 1201, 95% CI 1089–1423, per m/s), but not with age, body mass index, nor estimated glomerular filtration rate.


      Based on our data, SUA seems to be associated with an inadequate BP control in subjects treated with antihypertensive drugs, and subjects with both uncontrolled BP and relatively high SUA levels have also an increased arterial stiffness that (per se) could be a cause of worse BP control under treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Oda M.
        • Satta Y.
        • Takenaka O.
        • Takahata N.
        Loss of urate oxidase activity in hominoids and its evolutionary implications.
        Mol Biol Evol. 2002; 19: 640-653
        • Jin M.
        • Yang F.
        • Yang I.
        • Yin Y.
        • Luo J.J.
        • Wang H.
        • et al.
        Uric acid, hyperuricemia and vascular diseases.
        Front Biosci. 2012; 17: 656-669
        • Katsiki N.
        • Karagiannis A.
        • Athyros V.G.
        • Mikhailidis D.P.
        Hyperuricaemia: more than just a cause of gout?.
        J Cardiovasc Med. 2013; 14: 397-402
        • Bombelli M.
        • Ronchi I.
        • Volpe M.
        • Facchetti R.
        • Carugo S.
        • Dell'oro R.
        • et al.
        Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality.
        J Hypertens. 2014; 32: 1237-1244
        • Grayson P.C.
        • Kim S.Y.
        • LaValley M.
        • Choi H.K.
        Hyperuricemia and incident hypertension: a systematic review and meta-analysis.
        Arthritis Care Res. 2011; 63: 102-110
        • Zhao G.
        • Huang L.
        • Song M.
        • Song Y.
        Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies.
        Atherosclerosis. 2013; 231: 61-68
        • Bos M.J.
        • Koudstaal P.J.
        • Hofman A.
        • Witteman J.C.
        • Breteler M.M.
        Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study.
        Stroke. 2006; 37: 1503-1507
        • Sundström J.
        • Sullivan L.
        • D'Agostino R.B.
        • Levy D.
        • Kannel W.B.
        • Vasan R.S.
        Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence.
        Hypertension. 2005; 45: 28-33
        • Juraschek S.P.
        • Kovell L.C.
        • Miller E.R.
        • Gelber A.C.
        Dose–response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout.
        PLoS One. 2013; 8e56546
        • Cicero A.F.
        • D'Addato S.
        • Reggi A.
        • Reggiani G.M.
        • Borghi C.
        Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study.
        Intern Emerg Med. 2013; 8: 265-267
        • Cicero A.F.
        • D'Addato S.
        • Santi F.
        • Ferroni A.
        • Borghi C.
        • Brisighella Heart Study
        Leisure-time physical activity and cardiovascular disease mortality: the Brisighella Heart Study.
        J Cardiovasc Med. 2012; 13: 559-564
        • Cicero A.F.
        • Dormi A.
        • D'Addato S.
        • Borghi C.
        • on behalf of the Brisighella Heart Study Staff
        From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study.
        Clin Lipidol. 2011; 6: 269-276
        • Cicero A.F.
        • Reggi A.
        • Tartagni E.
        • Grandi E.
        • D'Addato S.
        • Borghi C.
        Brisighella Heart Study dietary determinants of oxidized-low-density lipoprotein antibodies in a sample of pharmacologically untreated non-smoker subjects: data from the Brisighella heart study.
        Adv Clin Exp Med. 2013; 22: 69-76
        • Cicero A.F.
        • Derosa G.
        • Rosticci M.
        • D'Addato S.
        • Agnoletti D.
        • Borghi C.
        • et al.
        Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: a 12-years follow-up of the Brisighella Heart Study historical cohort.
        Diabetes Res Clin Pract. 2014; 104: 183-188
        • Pickering TG
        • Hall JE
        • Appel LJ
        • Falker BE
        • Graves J.
        • Hill M.N.
        • Jones D.W.
        • Kurtz T.
        • Sheps S.G.
        • et al.
        Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.
        Circulation. 2005; 111: 697-716
        • Hickson S.S.
        • Butlin M.
        • Broad J.
        • Avolio A.P.
        • Wilkinson I.B.
        • McEniery C.M.
        Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device.
        Hypertens Res. 2009; 32: 1079-1085
        • Pucci G.
        • Cheriyan J.
        • Hubsch A.
        • Hickson S.S.
        • Gajendragadkar P.R.
        • Watson T.
        • et al.
        Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure.
        J Hypertens. 2013; 31: 77-85
        • Cicero A.F.
        • D'Addato S.
        • Veronesi M.
        • Rosticci M.
        • Santi F.
        • Dormi A.
        • et al.
        Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample: the Brisighella Heart Study.
        J Hypertens. 2012; 30: 492-496
        • Earley A.
        • Miskulin D.
        • Lamb E.J.
        • Levey A.S.
        • Uhlig K.
        Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review.
        Ann Intern Med. 2012; 156: 785-795
        • Mancia G.
        • Fagard R.
        • Narkiewicz K.
        • et al.
        Task force members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
        J Hypertens. 2013; 31: 1281-1357
        • Egan B.M.
        • Li J.
        • Hutchison F.N.
        • Ferdinand K.C.
        Hypertension in the United States, 1999 to 2012: progress toward healthy people 2020 goals.
        Circulation. 2014; 130: 1692-1699
        • Rapsomaniki E.
        • Timmis A.
        • George J.
        • Pujades-Rodriguez M.
        • Shah A.D.
        • Denaxas S.
        • et al.
        Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people.
        Lancet. 2014; 383: 1899-1911
        • Zhu P.
        • Lin F.
        • Lin C.
        • Hong D.
        • Lin K.
        • Chen H.
        Effect of hyperuricemia on the blood pressure response to antihypertensive agents in hospitalized elderly patients.
        J Cardiovasc Med. 2012; 13: 741-746
        • Brands M.W.
        Chronic blood pressure control.
        Compr Physiol. 2012; 2: 2481-2494
        • Feig D.I.
        • Kang D.H.
        • Johnson R.J.
        Uric acid and cardiovascular risk.
        N Engl J Med. 2008; 359: 1811-1821
        • Tomlinson L.A.
        Methods for assessing arterial stiffness: technical considerations.
        Curr Opin Nephrol Hypertens. 2012; 21: 655e60
        • Laurent S.
        Defining vascular aging and cardiovascular risk.
        J Hypertens. 2012; 30S3e8
        • Cicero A.F.
        • Salvi P.
        • D'Addato S.
        • Rosticci M.
        • Borghi C.
        Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study.
        J Hypertens. 2014; 32: 57-64
        • Mulè G.
        • Riccobene R.
        • Castiglia A.
        • D'Ignoto F.
        • Ajello E.
        • Geraci G.
        • et al.
        Relationships between mild hyperuricaemia and aortic stiffness in untreated hypertensive patients.
        Nutr Metab Cardiovasc Dis. 2014; 24: 744-750
        • Hsu P.F.
        • Chuang S.Y.
        • Cheng H.M.
        • Sung S.H.
        • Ting C.T.
        • Lakatta E.G.
        • et al.
        Associations of serum uric acid levels with arterial wave reflections and central systolic blood pressure.
        Int J Cardiol. 2013; 168: 2057-2063
        • Kanbay M.
        • Ozkara A.
        • Selcoki Y.
        • Isik B.
        • Turgut F.
        • Bavbek N.
        • et al.
        Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions.
        Int Urol Nephrol. 2007; 39: 1227-1233
        • Borghi C.
        • Verardi F.M.
        • Pareo I.
        • Bentivenga C.
        • Cicero A.F.
        Hyperuricemia and cardiovascular disease risk.
        Expert Rev Cardiovasc Ther. 2014; 12: 1219-1225
        • Tocci G.
        • Ferrucci A.
        • Pontremoli R.
        • Ferri C.
        • Rosei E.A.
        • Morganti A.
        • et al.
        Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000 to 2005 and 2005-2011 hypertension surveys.
        J Hum Hypertens. 2015; 29: 696-701
        • Mancia G.
        • Parati G.
        • Borghi C.
        • Ghironzi G.
        • Andriani E.
        • Marinelli L.
        • et al.
        Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study.
        J Hypertens. 2006; 24: 837-843
        • Klein A.V.
        • Kiat H.
        The mechanisms underlying fructose-induced hypertension: a review.
        J Hypertens. 2015; 33: 912-920